Our funders
NC3Rs funders
In 2022/23 the NC3Rs had a budget of £11.19M. The NC3Rs receives core funding from the MRC and BBSRC, which are part of UK Research and Innovation (UKRI). Core funding is reviewed every five years. In financial year 2022/23 the core funding was £10.2M. In addition to this, the NC3Rs received funding for specific programmes and posts and co-funding for awards from other research funders. In 2022/23, this included funding from the following organisations:
- Association of the British Pharmaceutical Industry (ABPI)*
- British Heart Foundation
- Cancer Research UK
- Engineering and Physical Sciences Research Council
- GSK
- Shell
- Syngenta
- Corteva Agriscience
- Unilever
- Wellcome
- Bill and Melinda Gates Foundation
- The Francis Crick Institute
- Great Western 4 Alliance (University of Bath, University of Bristol, Cardiff University and University of Exeter)
- King’s College London
- London School of Hygiene and Tropical Medicine
- Royal Veterinary College
- University College London
- University of Birmingham
- University of Leicester
- University of Nottingham
- University of Oxford
* in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance Laboratories, Charles River Laboratories and UCB Pharma.
Budget
Table 1 shows the NC3Rs income and expenditure for the financial year 2022/23. Expenditure is divided across three areas – research and innovation awards made to universities and SMEs, support for early career researchers (e.g. funding for PhD studentships) and programmes led by NC3Rs scientific staff.
Table 1: Income and expenditure
Type |
Amount £M |
---|---|
Income | - |
Core | 10.2 |
Non-core | 0.99 |
Expenditure | - |
Research and innovation awards | 6.37 |
Early career awards | 1.51 |
Science programmes led by NC3Rs staff | 3.23 |